[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 1985

News and Notes

Arch Dermatol. 1985;121(1):34. doi:10.1001/archderm.1985.01660010038015

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


New Name. Same Power. Lidex (fluocinonid) × 0.05% y Brief Summary of Prescribing Information LIDEX® (fluocinonide) Gel 0.05% Description: LIDEX gel 0.05% is intended for topical administration. The active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11 -hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6α,11β,16α)LIDEX gel contains fluocinonide 0.5 mg/g in a specially formulated gel base consisting of propylene glycol, propyl gallate, edetate disodium, and carbomer 940, with NaOH and/or HCl added to adjust the pH. This clear, colorless thixotropic vehicle is greaseless, non-staining and completely water miscible In this formulation, the active ingredient is totally in solution. Indications: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses Contraindications: Hypersensitivity to any ingredient. Precautions General Periodically evaluate patients given a large dose of a potent topical steroid applied to a large area or under occlusive dressing for HPA suppression by using urinary free cortisol and

First Page Preview View Large
First page PDF preview
First page PDF preview